Journal article
The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial
W Marx, DR Skvarc, M Mohebbi, AJ Walker, A Meehan, A Turner, A Baker, S Dodd, SM Cotton, JG Scott, BE Kavanagh, MM Ashton, E Brown, JJ McGrath, M Berk, OM Dean
Frontiers in Psychiatry | FRONTIERS MEDIA SA | Published : 2021
Open access
Abstract
Background: Cognitive impairment is prevalent and often highly burdensome in people with schizophrenia. The aim of this study was to investigate if mangosteen (Garcinia mangostana Linn.) pericarp extract may be an effective intervention to improve cognitive performance in this population. Methods: This was a secondary analysis of a larger randomized placebo-controlled trial that investigated a 24-weeks intervention of mangosteen pericarp extract supplementation in people diagnosed with schizophrenia. A subset of n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: ..
View full abstractGrants
Awarded by Stanley Medical Research Institute
Funding Acknowledgements
The primary study was funded by the Stanley Medical Research Institute (Treatment Trial #14T-007). All authors gratefully acknowledge their support. We wish to thank the participants who took part in the study, the health services including Barwon Health, the West Moreton Hospital and Health Service, the Metro North Mental Health Service, Metro South Mental Health Service, Gold Coast Mental Health Service, the Melbourne Clinic and the Community and Research Network. MB was supported by a NHMRC Senior Principal Research Fellowship 1059660 and 1156072. JM was supported by grant APP1056929 from the John Cade Fellowship from the National Health and Medical Research Council. OD was supported by a NHMRC R.D. Wright Career Development Fellowship (1145634).